Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7768583 | 0.89 | CYP3A4 (0.53) | CYP3A4 | |
| SCHEMBL27822413 | 0.84 | POLB (0.47) | — | |
| SCHEMBL25284051 | 0.84 | CYP3A4 (0.47) | CYP3A4 | |
| SCHEMBL31495237 | 0.83 | CYP3A4 (0.53) | CYP3A4 | |
| SCHEMBL19904729 | 0.82 | TSHR (0.55) | CYP3A4 | |
| SCHEMBL27042296 | 0.82 | KMT2A (0.50) | CYP3A4 | |
| SCHEMBL3229774 | 0.82 | CYP3A4 (0.46) | CYP3A4 | |
| SCHEMBL124571 | 0.81 | CYP3A4 (0.55) | CYP3A4 | |
| SCHEMBL31169485 | 0.81 | CYP3A4 (0.47) | CYP3A4 | |
| SCHEMBL16023560 | 0.80 | KMT2A (0.58) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260015372-A1 | Organophosphorous Compounds and Uses Thereof | JAL THERAPEUTICS LLC (US) | 2026-01-15 | — | — | US | claimed |
| WO-2024020507-A2 | ORGANOPHOSPHOROUS COMPOUNDS AND USES THEREOF | JAL THERAPEUTICS, LLC (US) | 2024-01-25 | — | — | WO | claimed |
| US-20260015372-A1 | Organophosphorous Compounds and Uses Thereof | JAL THERAPEUTICS LLC (US) | 2026-01-15 | — | — | US | disclosed |
| WO-2024020507-A2 | ORGANOPHOSPHOROUS COMPOUNDS AND USES THEREOF | JAL THERAPEUTICS, LLC (US) | 2024-01-25 | — | — | WO | disclosed |
| US-20180104263-A1 | BUTYRYLCHOLINESTERASE INHIBITORS | JAL THERAPEUTICS, LLC | 2018-04-19 | — | — | US | disclosed |
| US-20180104263-A1 | BUTYRYLCHOLINESTERASE INHIBITORS | JAL THERAPEUTICS, LLC | 2018-04-19 | — | — | US | disclosed |
| US-20180104263-A1 | BUTYRYLCHOLINESTERASE INHIBITORS | JAL THERAPEUTICS, LLC | 2018-04-19 | — | — | US | disclosed |
| EP-2097428-B1 | BUTYRYLCHOLINESTERASE INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | MGP BIOTECHNOLOGIES INC (US) | 2018-02-28 | — | — | EP | disclosed |
| EP-2097428-B1 | BUTYRYLCHOLINESTERASE INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | MGP BIOTECHNOLOGIES INC (US) | 2018-02-28 | — | — | EP | disclosed |
| US-9757399-B2 | Butyrylcholinesterase inhibitors | JAL THERAPEUTICS, INC. (US) | 2017-09-12 | — | — | US | disclosed |
| US-9757399-B2 | Butyrylcholinesterase inhibitors | JAL THERAPEUTICS, INC. (US) | 2017-09-12 | — | — | US | disclosed |
| US-20140073608-A1 | Butyrylcholinesterase Inhibitors | MGP BIOTECHNOLOGIES, LLC (US) | 2014-03-13 | — | — | US | disclosed |
| US-20140073608-A1 | Butyrylcholinesterase Inhibitors | MGP BIOTECHNOLOGIES, LLC (US) | 2014-03-13 | — | — | US | disclosed |
| US-20140073608-A1 | Butyrylcholinesterase Inhibitors | MGP BIOTECHNOLOGIES, LLC (US) | 2014-03-13 | — | — | US | disclosed |
| US-20100069337-A1 | BUTYRYLCHOLINESTERASE INHIBITORS | JAL THERAPEUTICS, LLC | 2010-03-18 | — | — | US | disclosed |
| US-20100069337-A1 | BUTYRYLCHOLINESTERASE INHIBITORS | JAL THERAPEUTICS, LLC | 2010-03-18 | — | — | US | disclosed |
| US-20100069337-A1 | BUTYRYLCHOLINESTERASE INHIBITORS | JAL THERAPEUTICS, LLC | 2010-03-18 | — | — | US | disclosed |
| EP-2097428-A2 | BUTYRYLCHOLINESTERASE INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | Mgp Biotechnologies, Inc. (US) | 2009-09-09 | — | — | EP | disclosed |
| WO-2008055249-A2 | BUTYRYLCHOLINESTERASE INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | MGP BIOTECHNOLOGIES, INC. (US) | 2008-05-08 | — | — | WO | disclosed |
| WO-2008055249-A2 | BUTYRYLCHOLINESTERASE INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | MGP BIOTECHNOLOGIES, INC. (US) | 2008-05-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180104263-A1 | BUTYRYLCHOLINESTERASE INHIBITORS | BCHE, ACHE, PSEN1 | CYP3A4 1055/4885 |
| US-20140073608-A1 | Butyrylcholinesterase Inhibitors | BCHE, ACHE, PSEN1 | CYP3A4 1055/4885 |
| US-20100069337-A1 | BUTYRYLCHOLINESTERASE INHIBITORS | BCHE, ACHE, PSEN1 | CYP3A4 1055/4885 |
| US-20260015372-A1 | Organophosphorous Compounds and Uses Thereof | ACHE, BCHE, MUSK | CYP3A4 1005/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.